Delhi’s APAC Biotech bags patent for personalized immunotherapy based cancer treatment
- by Team ABLE - 28 Jul, 2020
APAC Biotech, an Indian biotechnology company involved in extensive research on personalized immunotherapy using dendritic cells for over a decade, was granted Indian patent (340947), entitled "COMPOSITION AND METHOD FOR PRODUCING ACTIVATED DENDRITIC CELLS".
The company has previously conducted trials and received the approval by the Drug Controller General of India in 2017 for its product APCEDEN (personalized dendritic cell-based immunotherapy). Being completely autologous in nature, it has been successfully infused to patients with an excellent safety profile and efficacy.
APAC BIOTECH's new product is named LTR-MEMVAXRALEUCEL, which based on homogenous loading of whole tumor amplified mRNA and whole tumor protein, specifically designed for Glioblastoma and Pancreatic Ductal Adenocarcinoma for which clinical trial is awaited, and APAC BIOTECH is in talks with various hospitals and principal investigators to initiate the trial in India very soon.
"We are proud to acknowledge that APCEDEN is a completely Make in India product. With the Indian FDA approval and Indian patent, we hope to raise investments to expand our operations PAN India and help the cause of cancer treatment. We are also looking at global partners to expand our operations on a technology transfer basis," commented Mr Arun Mehra, CEO, APAC Biotech.
About the patent, APAC Biotech's present invention provides a composition comprising of a population of activated dendritic cells tutored in the lab to produce immunogens useful in the treatment of cancer. The invention also provides a method for producing a population of activated dendritic cells specific to a patient's whole tumor protein. Most significantly, the procedures used to manufacture dendritic cells replicate the natural environment of the human host very closely.
APCEDEN – APAC’s immunotherapy product, has already been approved by the Indian FDA for treating cancer. The company has further announced it will conduct clinical trials for highly aggressive brain tumors